Editorial
Tumor mutation burden in lung cancer: a new predictive biomarker for immunotherapy or too soon to tell?
Abstract
Immunotherapy with immune-checkpoint inhibitors (ICIs) has shifted the therapeutic landscape in lung cancer. At the same time, the clinical benefits of ICIs in unselected patients remain modest.
